Aerie Pharmaceuticals files for proposed initial public offering

Aerie Pharmaceuticals has filed an S-1 registration statement with the U.S. Securities and Exchange Commission involving a proposed initial public offering of common stock, according to a company news release.The price range and number of shares to be sold on behalf of Aerie, a clinical-stage company focused on therapies to treat patients with glaucoma and other eye diseases, have not been determined, the release said.

Full Story →